An Adherence-Enhancing Program Increases Retention in Care in the Swiss HIV Cohort.
HIV
adherence intervention
antiretrovirals
interprofessionality
medication retention in care
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
29
04
2020
accepted:
10
08
2020
entrez:
11
9
2020
pubmed:
12
9
2020
medline:
12
9
2020
Statut:
epublish
Résumé
This study tested a theory-based adherence-enhancing intervention: the "Interprofessional Medication Adherence Program" (IMAP) to increase human immunodeficiency virus (HIV) retention in care. We retrospectively compared our intervention center (intervention group [IG]) with a standard of care center (control group [CG]) both participating in the Swiss HIV Cohort Study between 2004 and 2012. Endpoints were defined as >6-month and >12-month gaps in care for intervals of care longer than 6 and 12 months without any blood draw. Inverse probability of treatment weights was used to adjust for differences between patients at the 2 centers. Viral failure was defined as ribonucleic acid ≥50 copies/mL after 24+ weeks on antiretrovirals. The IG included 451 patients, CG 311. In the IG, 179 (40%) patients took part in the IMAP for a median of 27 months (interquartile range, 12-45). Gaps in care of ≥6 months were significantly more likely to happen in the CG versus IG (74.6% vs 57%, This study, in a real-world setting, shows the effectiveness of the IMAP to reduce 6- and 12-month gaps in follow up among people with HIV. These results should be confirmed by studies in other settings.
Sections du résumé
BACKGROUND
BACKGROUND
This study tested a theory-based adherence-enhancing intervention: the "Interprofessional Medication Adherence Program" (IMAP) to increase human immunodeficiency virus (HIV) retention in care.
METHODS
METHODS
We retrospectively compared our intervention center (intervention group [IG]) with a standard of care center (control group [CG]) both participating in the Swiss HIV Cohort Study between 2004 and 2012. Endpoints were defined as >6-month and >12-month gaps in care for intervals of care longer than 6 and 12 months without any blood draw. Inverse probability of treatment weights was used to adjust for differences between patients at the 2 centers. Viral failure was defined as ribonucleic acid ≥50 copies/mL after 24+ weeks on antiretrovirals.
RESULTS
RESULTS
The IG included 451 patients, CG 311. In the IG, 179 (40%) patients took part in the IMAP for a median of 27 months (interquartile range, 12-45). Gaps in care of ≥6 months were significantly more likely to happen in the CG versus IG (74.6% vs 57%,
CONCLUSIONS
CONCLUSIONS
This study, in a real-world setting, shows the effectiveness of the IMAP to reduce 6- and 12-month gaps in follow up among people with HIV. These results should be confirmed by studies in other settings.
Identifiants
pubmed: 32913876
doi: 10.1093/ofid/ofaa323
pii: ofaa323
pmc: PMC7473741
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa323Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
AIDS Care. 2008 Mar;20(3):273-83
pubmed: 18351473
Br J Clin Pharmacol. 2012 May;73(5):691-705
pubmed: 22486599
AIDS. 2002 May 3;16(7):1051-8
pubmed: 11953472
AIDS Care. 2011 May;23(5):550-61
pubmed: 21271406
AIDS. 2006 Jan 9;20(2):143-57
pubmed: 16511407
J Antimicrob Chemother. 2010 Jun;65(6):1100-7
pubmed: 20348088
J Acquir Immune Defic Syndr. 2013 Nov 1;64 Suppl 1:S33-41
pubmed: 23982662
Clin Infect Dis. 2013 May;56(9):1319-26
pubmed: 23249611
Int J Clin Pharm. 2012 Jun;34(3):426-31
pubmed: 22527483
Clin Infect Dis. 2011 Mar 15;52(6):793-800
pubmed: 21367734
AIDS Behav. 2020 Apr;24(4):985-997
pubmed: 31555931
BMC Fam Pract. 2010 Oct 25;11:79
pubmed: 20973950
Annu Rev Pharmacol Toxicol. 2012;52:275-301
pubmed: 21942628
Patient Educ Couns. 2018 Sep;101(9):1676-1682
pubmed: 29871817
J Int AIDS Soc. 2018 Sep;21(9):e25176
pubmed: 30240121
J Acquir Immune Defic Syndr. 2006 Mar;41(3):385-92
pubmed: 16540942
AIDS Patient Care STDS. 2010 Oct;24(10):607-13
pubmed: 20858055
AIDS Care. 2012;24(5):583-92
pubmed: 22292452
Epidemiology. 2003 Nov;14(6):680-6
pubmed: 14569183
Biomed Res Int. 2015;2015:103546
pubmed: 26839879
AIDS Care. 2002 Aug;14 Suppl 1:S45-57
pubmed: 12204141
J Acquir Immune Defic Syndr. 2010 Jun;54(2):197-203
pubmed: 20035231
J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):333-9
pubmed: 24129370
J Antimicrob Chemother. 2007 Sep;60(3):461-3
pubmed: 17609196
AIDS. 2001 Jun 15;15(9):1181-3
pubmed: 11416722
Clin Infect Dis. 2016 Mar 1;62(5):648-654
pubmed: 26567263
Clin Infect Dis. 2014 Jul;59 Suppl 1:S21-7
pubmed: 24926028
Ann Intern Med. 2012 Jun 5;156(11):817-33, W-284, W-285, W-286, W-287, W-288, W-289, W-290, W-291,
pubmed: 22393036
Curr HIV/AIDS Rep. 2012 Dec;9(4):313-25
pubmed: 22996171
Pharm World Sci. 2010 Dec;32(6):776-86
pubmed: 20862544
J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):387-99
pubmed: 26959190
Epidemiology. 2000 Sep;11(5):550-60
pubmed: 10955408
Clin Infect Dis. 2007 Jun 1;44(11):1493-9
pubmed: 17479948
Infect Dis Clin North Am. 2014 Sep;28(3):355-69
pubmed: 25151561
Clin Infect Dis. 2006 Jul 15;43(2):234-42
pubmed: 16779752
J Consult Clin Psychol. 2003 Oct;71(5):843-61
pubmed: 14516234
Clin Infect Dis. 2009 Jan 15;48(2):248-56
pubmed: 19072715
Curr HIV/AIDS Rep. 2010 Nov;7(4):234-44
pubmed: 20820972
AIDS Care. 2002 Aug;14 Suppl 1:S31-44
pubmed: 12204140
J Assoc Nurses AIDS Care. 2007 May-Jun;18(3):33-41
pubmed: 17570298
BMC Health Serv Res. 2019 Jan 8;19(1):15
pubmed: 30621697
Annu Rev Clin Psychol. 2005;1:91-111
pubmed: 17716083
Health Psychol. 2009 Nov;28(6):668-74
pubmed: 19916634
J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):622-30
pubmed: 23614992